Abstract 898P
Background
Oral mucositis (OM) is severe in up to 70% of patients receiving standard chemoradiation (7 weeks of RT and concurrent cisplatin). Cisplatin contributes to the acute toxicity (acute kidney injury, tinnitus, myelosuppression) during treatment but also causes irreversible chronic kidney disease (CKD) in up to 30% of patients in the years following treatment. Two randomized, placebo-controlled, blinded studies, ROMAN (NCT03689712) and GT-201 (NCT02508389), evaluated avasopasem 90mg (AVA) for the reduction of severe OM (SOM, WHO grade 3-4) and both met their primary endpoints.
Methods
The ROMAN phase 3 (ITT N=407) and GT-201 phase 2b trials (ITT placebo and 90 mg N=144) results were aggregated using conventional methods for fixed-effects meta-analysis. In ROMAN, prospectively defined follow-up of serum creatinine (sCr) and estimated glomerular filtration rates (eGFR) were assessed every 3 months for 1 year following 7 weeks of CRT.
Results
The meta-analysis of ROMAN and GT-201 (N=551 [313 AVA/238 PBO]) showed a 19% relative reduction in SOM incidence (52% vs 64%; P=0.0053), 58% relative reduction in SOM duration (median, 8 vs 19 days; P=0.0002), 32% reduction in Grade 4 incidence (22% vs 32%; P=0.0102), and 28% delay in median days to SOM onset (median 50 vs 39 days; P=0.0005). Adverse event frequencies were mostly comparable between treatment groups with a trend towards reduction of certain IMRT- and cisplatin-related toxicities including tinnitus which was reported less with AVA in both studies. At 1-year follow-up, AVA was associated with significant improvements in preservation of eGFR (P=0.0008) and sCr (P=0.006) levels vs PBO. Grade 3+ CKD results through 12 months show 10% AVA vs 20% PBO (relative risk 0.55, P=0.0043).
Conclusions
AVA produced statistically significant, clinically meaningful improvement of SOM vs PBO that was consistent across multiple measures of SOM, with an adverse event profile consistent with expectations for IMRT/cisplatin. At 1-year follow-up, AVA appears to reduce cisplatin-related CKD in the study population.
Clinical trial identification
GTI-4419-301, 13 July 2020 (NCT03689712).
Editorial acknowledgement
Editorial (Sarah Hummasti, PhD) was provided by AOIC, LLC and funded by Galera Therapeutics, Inc.
Legal entity responsible for the study
Galera Therapeutics, Inc.
Funding
Galera Therapeutics, Inc.
Disclosure
N. Dunlap: Financial Interests, Personal, Speaker, Consultant, Advisor: AstraZeneca. C. Anderson: Non-Financial Interests, Personal and Institutional, Speaker, Consultant, Advisor: Galera Therapeutics, Inc. C. Lee: Financial Interests, Personal and Institutional, Research Funding: Bayer, Merck, Decipher Genetics; Financial Interests, Personal and Institutional, Advisory Role: Bayer, Merck, Decipher Genetics; Financial Interests, Personal, Stocks or ownership: Axcend LLC, Kobold Medical LLC. J. Kelley: Financial Interests, Personal and Institutional, Research Funding: Galera Therapeutics, Inc. G. Walker: Financial Interests, Personal, Advisory Role: Galera Therapeutics, Inc.; Financial Interests, Personal and Institutional, Research Funding: Galera Therapeutics, Inc. V. Bar-Ad: Financial Interests, Personal and Institutional, Research Funding: Galera Therapeutics, Inc. D. Miller: Financial Interests, Personal and Institutional, Research Funding: Galera Therapeutics, Inc. V. King: Financial Interests, Personal, Ownership Interest: San Juan Cancer Center; Financial Interests, Personal, Leadership Role: San Juan Cancer Center. A. Peddada: Financial Interests, Personal, Stocks/Shares: Galera Therapeutics, Inc. D. Ciuba: Financial Interests, Personal and Institutional, Research Funding: Galera Therapeutics, Inc. F. Vincent: Financial Interests, Personal and Institutional, Research Funding: Galera Therapeutics, Inc. B. Muzyka: Financial Interests, Institutional, Research Funding: Galera Therapeutics, Inc. A. Gillespie-Twardy: Financial Interests, Personal and Institutional, Research Funding: Galera Therapeutics, Inc. S. Sonis: Financial Interests, Personal, Full or part-time Employment: Primary Endpoint Solutions ; Financial Interests, Personal, Leadership Role: Primary Endpoint Solutions ; Financial Interests, Institutional, Other, Contract work for study: Galera Therapeutics, Inc. E. Kennedy: Financial Interests, Personal, Full or part-time Employment: Galera Therapeutics, Inc.; Financial Interests, Personal, Stocks or ownership: Galera Therapeutics, Inc. D. Saunders: Financial Interests, Personal and Institutional, Research Funding: Galera Therapeutics, Inc.
Resources from the same session
922P - Dose expansion results of the bifunctional EGFR/TGFβ inhibitor BCA101 with pembrolizumab in patients with recurrent, metastatic head and neck squamous cell carcinoma
Presenter: Glenn Hanna
Session: Poster session 12
923P - Phase II trial evaluating the efficacy of pembrolizumab combined with vorinostat in patients with recurrent and/or metastatic head & neck squamous cell carcinoma – subgroup analysis of the PEVOsq basket trial
Presenter: Christophe Le Tourneau
Session: Poster session 12
924P - Polyfunctional HPV16-Specific T cell responses in subjects receiving PDS0101 and pembrolizumab combination treatment for recurrent/metastatic HPV16-positive head and neck squamous cell carcinoma (HNSCC)
Presenter: Kevin Harrington
Session: Poster session 12
925P - Treatment discontinuation of immune checkpoint blockade in patients with head and neck squamous cell carcinoma experiencing complete or nearly complete remission
Presenter: Konrad Klinghammer
Session: Poster session 12
926P - UK national real-world outcome data of first-line pembrolizumab treatment in head and neck squamous cell cancer (HNSCC)
Presenter: Ifigenia Vasiliadou
Session: Poster session 12
927P - Patients (pts) with recurrent and/or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN) treated with nivolumab (NIVO) in the first-line (1L) or later-line (2L+) settings in Germany: Updated results from the real-world HANNA study
Presenter: Boris Kubuschok
Session: Poster session 12
928P - Prognostic value of body composition and nutritional assessment in recurrent/metastatic squamous cell carcinoma of head and neck (R/M SCCHN) treated with immunotherapy (IO)
Presenter: Zara Vidales Sepulveda
Session: Poster session 12
930P - Platinum and taxane (PT) plus immunotherapy versus immunotherapy alone in patients with recurrent/metastatic (R/M) head and neck cancer (HNSCC)
Presenter: Marcelo Bonomi
Session: Poster session 12
931P - Early recurrence, time-to-recurrence, and recurrence patterns: Assessing their impact on survival outcomes in recurrent/metastatic head and neck squamous cell carcinoma (R/M-HNSCC) patients
Presenter: Pasvich Pitakpaiboonkul
Session: Poster session 12